EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer

Jing Cheng, Wenwen Kang, Yueying Chen, Luyun Pan, Hedong Han, Tangfeng Lv

Cancer Immunology, Immunotherapy · 25.02.2025 · 74 (4)

DOI: 10.1007/s00262-025-03958-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 25.02.2025. Verfasst von Jing Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, J…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, Clinical Research Project of Jinling Hospital, Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The benefits of continuing immunotherapy beyond disease progression in advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain uncertain, along with the specific patient subgroups that may gain the most from this approach. This retrospective study aims to evaluate the efficacy of this approach and identify target patient populations likely to benefit. METHODS: We collected data from patients with NSCLC and SCLC who experienced disease progression following initial immune checkpoint inhibitor (ICI) treatment from January 2020 to December 2023. Patients were categorized based on second-line treatment: those receiving immunotherapy beyond progression (IBP) and those receiving non-immunotherapy beyond progression (NIBP). Survival outcomes and treatment safety were compared between these two groups. RESULTS: A total of 150 patients were included, with 111 NSCLC patients (IBP: n = 78, NIBP: n = 33) and 39 SCLC patients (IBP: n = 31, NIBP: n = 8). Significant differences in median progression-free survival (PFS) and overall survival (OS) were found in patients with driver gene-negative NSCLC (mPFS: 4.7 vs 1.3 months, HR = 0.29, P < 0.01; mOS: 11.03 vs 2.63 months, HR = 0.13, P < 0.001) and SCLC (mPFS: 3.9 vs 2.1 months, HR = 0.38, P = 0.02; mOS: 9.28 vs 2.27 months, HR = 0.23, P < 0.01). Additionally, among driver gene-negative NSCLC patients, achieving a partial response (PR) or stable disease (SD) during initial immunotherapy was associated with improved effectiveness of continued immunotherapy beyond progression. CONCLUSIONS: Continued immunotherapy as a second-line treatment may benefit patients with driver gene-negative NSCLC and SCLC who have progressed after initial immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaLung NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesDisease ProgressionMiddle AgedAgedAged, 80 and overAdult

Stichwörter der Autor:innen

EfficacyImmune checkpoint inhibitors (ICIs)Immunotherapy beyond progression (IBP)Non-small cell lung cancer (NSCLC)Small cell lung cancer (SCLC)

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
  • Department of Respiratory and Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. he_dong1102@126.com.
  • Department of Respiratory and Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. TangfengLv7210@nju.edu.cn.

Förderung

  • Natural Science Foundation of Jiangsu Province
  • Clinical Research Project of Jinling Hospital
  • Natural Science Foundation of China

Zitieren

APA

Cheng, J., Kang, W., Chen, Y., Pan, L., Han, H., & Lv, T. (2025). Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer. Cancer Immunology, Immunotherapy, 74(4). https://doi.org/10.1007/s00262-025-03958-9

Vancouver

Cheng J, Kang W, Chen Y, Pan L, Han H, Lv T. Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer. Cancer Immunology, Immunotherapy. 2025;74(4). doi:10.1007/s00262-025-03958-9

BibTeX
@article{Cheng2025,
  author = {Cheng, Jing and Kang, Wenwen and Chen, Yueying and Pan, Luyun and Han, Hedong and Lv, Tangfeng},
  title = {Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {4},
  doi = {10.1007/s00262-025-03958-9}
}
Kostenlos starten →